Severe Intoxication with Methotrexate Possibly Associated with Concomitant Use of Proton Pump Inhibitors

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 963-966

  Santucci, Raoul ^a   Levêque, Dominique ^a   Kemmel, Véronique ^a   Lutz, Patrick ^a   Gérout, Anne Cécile ^a   N'Guyen, Aurélia ^a   Lescoute, Aurélie ^a   Schneider, Francis ^a   Bergerat, Jean Pierre ^a   Herbrecht, Raoul ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Drug drug interaction; Glucarpidase; Methotrexate; Proton pump inhibitor

Indexed keywords

CARBOXYPEPTIDASE G2; CREATININE; ESOMEPRAZOLE; LANSOPRAZOLE; METHOTREXATE; OMEPRAZOLE; PANTOPRAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG ANTAGONISM; DRUG ELIMINATION; DRUG INTOXICATION; DRUG MEGADOSE; HUMAN; HYDRATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; GAMMA-GLUTAMYL HYDROLASE; HUMANS; LYMPHOMA; METHOTREXATE; MIDDLE AGED; NEUROBLASTOMA; OSTEOSARCOMA; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77951033350     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Messmann RA and Allegra CJ: Antifolates. In: Cancer Chemotherapy and Biotherapy. Chabner BA, Longo DL (eds.). Philadelphia, Lippincott Williams & Wilkins, pp. 139-184, 2001.
2. Thyss A, Milano G, Kubar J, Namer M and Schneider M: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1: 256-258, 1986.
3. Dalle J-H, Auvrignon A, Vassal G and Leverger G: Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol/Oncol 24: 321-322, 2002.
4. Zarychanski R, Wlodarczyk K, Ariano R and Bow E: Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentration of methotrexate. J Antimicrob Chemother 58: 228-230, 2006.
5. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T and Sugiyama Y: Species differences in the inhibitory effect of nonsteroidal antiinflammatory drugs on the uptake of methotrexate by human kidney cells. J Pharmacol Exp Ther 322: 1162-1170, 2007.
6. Benet L and Hoerner BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71: 115-121, 2002.
7. Reid T, Yuen A, Catolico M and Carlson RW: Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol 33: 82-84, 1993.
8. Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L and Giraldez J: Potential interaction between methotrexate and omeprazole. Ann Pharmacother 34: 1024-1027, 2000.
9. Tröger U, Stötzel B, Martens-Lobenhoffer J, Gollnick H and Meyer FP: Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br Med J 324: 1497, 2002.
10. Joerger M, Huitema A DR, Van den Bongard H JGD, Baas P, Schornagel JH, Schellens JHM and Beijnen JH: Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 62: 71-80, 2005.
11. Bauters TGM, Verlooy J, Robays H and Laureys G: Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci 30: 316-318, 2008.
12. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y and Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67: 44-49, 2009.
13. Breedveld P, Zelcer N, Pluim D, Sönmezer Ö, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P and Schellens JHM: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64: 5804-5811, 2004.
14. Widemann BC and Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 11: 694-703, 2006.
15. Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G, Bode U and Fleischhack G: Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 92: 480-487, 2005.
16. Whelan J, Hoare D and Leonard P: Omeprazole does not alter plasma methotrexate clearance. Cancer Chemother Pharmacol 44: 88-89, 1999.
17. Huls M, Brown CDA, Windass AS, Sayer R, van den Heuvel JJMW, Heemskerk S, Russel FGM and Masereeuw R: The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73: 220-225, 2008.